Can AI Be Licensed the Way Doctors and Nurses Are?
A Licensure Model May Offer Safer Oversight as Clinical AI Grows More Complex, a Penn LDI Doctor Says
News
Aaron Schwartz Wins 2022 SGIM Award
Penn LDI Senior Fellow Honored for Scientific Presentation
Print:
LDI Senior Fellow and Perelman School of Medicine Assistant Professor Aaron Schwartz, MD, PhD, has received a 2022 Junior Faculty Scientific Presentation Award from the Society of General Internal Medicine (SGIM). The awards ceremony was part of the organization’s April 9 Annual Meeting in Orlando, Florida.
Dr. Schwartz was presented with a Milton W. Hamolsky Junior Faculty Scientific Presentation Award for his paper, “Variation in Low-Value Service Use Across Veterans Affairs Facilities.”
A U.S. professional society whose 3,300 members are engaged in internal medicine research and teaching, SGIM is publisher of the Journal of General Internal Medicine. The annual awards are endowed by the Zlinkoff Fund for Medical Education.
Dr. Schwartz’s research focuses on understanding and improving health care efficiency and quality. Recent projects have examined the use of low-value care in Medicare, the incentive properties of hospital performance measures, and the role of private and public insurer coverage rules.
More LDI News
Venture Philanthropy Transformed Cystic Fibrosis. Can It Deliver for Other Diseases?
CF Foundation’s Landmark Drug Approvals With Vertex Inspired Patient Groups to Act Like Biotech Investors. But Only a Few Groups Have Made Big Bets, LDI Fellow Finds
Meaningful Representation in Clinical Trials Strengthens Science
Failure to Include Diverse Populations Undermines Innovation in the Age of Precision Medicine
Three Studies by LDI Senior Fellows Win Clinical Research Forum Awards
Chen and Roberts in Top 10, Groeneveld a Top 10 Finalist
Unpacking the Federal Drug Price Reduction Struggle
How Political Rhetoric and Behind-the-Scenes Deal-Making Obscure Who Really Pays – or How Much
Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic
Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools